US FDA proposes new rule to simplify drug manufacturing registration
The agency said the rule would improve supply chain transparency, enhance product traceability, reduce registration costs and increase regulatory efficiency if finalised
Read the full articleYou might also wanna read
FDA Moves to Speed Biosimilar Development, Lower Prescription Drug Costs
The FDA has unveiled draft guidance to accelerate biosimilar approvals, reduce testing costs, and expand access to affordable biologic alter
FDA Issues Draft Guidance on Responding to Form 483 Observations
In March 2026, the U.S. Food and Drug Administration (FDA or the Agency) issued the draft guidance for industry, Responding to FDA Form 483
Streamlined and Sponsor-Friendly: What China’s Amended Drug Regulations Mean for Pharma Companies
On January 27, 2026, China’s State Council published the amended Implementing Regulations of the Drug Administration Law, which will take ef
FDA Proposes Revised Payor Communications Draft Guidance to Formally Include Devices and Reflect New Statutory Safe Harbor While Balancing Substantial Government Interests
The U.S. Food and Drug Administration’s 2026 Draft Payor Guidance would update the framework for communications between drug and device manu
FDA's AI for Drug Approvals Found to Fabricate Studies
The FDA’s new AI designed to speed up drug approvals has been found to fabricate studies and misrepresent research. What do you think?
The Onion·11mo ago
Independent US body finds drug shortages are lasting longer as reliability dwindles
The US Pharmacopeia’s new sweeping report shows shortages are lingering as supply lines falter.
Comments
Sign in to join the conversation.
No comments yet. Be the first.